Zodasiran
Phase 3RNA therapy
Arrowhead PharmaceuticalsZodasiran is one of 3 small molecule programs targeting Homozygous Familial Hypercholesterolemia. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Homozygous Familial Hypercholesterolemia
#DrugCompanyPhaseTrials
1Leqvio
NovartisPhase 3
SHR-1918
BBeijing Suncadia Pharmaceuticals Co., Ltd
Phase 3
Zodasiran
Arrowhead PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zodasiran. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- RNA therapy[2]
- Highest Phase
- Phase 3[1]
- Company